CLLS - Cellectis S.A.
| Previous Close | 12.51 |
| Open | 12.54 |
| Bid | 10.20 x 1000 |
| Ask | 14.37 x 1000 |
| Day's Range | 12.06 - 12.60 |
| 52 Week Range | 11.70 - 29.97 |
| Volume | 95,153 |
| Avg. Volume | 121,371 |
| Market Cap | 518.487M |
| Beta (3Y Monthly) | 1.54 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.24 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 40.18 |
- Business Wire
Cellectis Reports Financial Results for Second Quarter and First Six Months 2019
NEW YORK-- -- FDA approved IND for UCARTCS1 – first allogeneic CAR T-cell product candidate in multiple myeloma Ongoing construction of in-house manufacturing facilities: IMPACT in Raleigh, NC and SMART in Paris, France Published novel manufacturing methods to improve allogeneic CAR T-cell safety and purity Published next generation CAR design with an embedded On/Off-Switch to increase safety for patients ...
- Business Wire
Cellectis Publishes New CAR Design to Control CAR T-Cells in Non-Lethal Way
SWIFF-CAR, a Next Generation CAR with an Embedded On/Off-Switch Increases Safety for Patients and Extends Manufacturing Possibilities
- Business Wire
Cellectis S.A. Reports Results from Combined Shareholders Meeting Held on June 25, 2019
Regulatory News:
- Business Wire
Cellectis Reports Financial Results for First Quarter 2019
- Started construction of in-house manufacturing facilities IMPACT and SMART
- Business Wire
Cellectis Announces Oral and Poster Presentations of Allogeneic CAR T-Cell Programs at the 2019 ASGCT Annual Meeting
- Oral presentation to include preclinical UCARTCS1A data in Multiple Myeloma
- Benzinga
The Daily Biotech Pulse: Advaxis Offering, Roche's Spark Tender Offer Extended, Ascendis Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 2) Denali Therapeutics Inc (NASDAQ: DNLI ) Dr.Reddy's ...
- Business Wire
FDA Clears the IND for UCARTCS1, the First Allogeneic CAR-T to Treat Multiple Myeloma Patients
Cellectis (Euronext Growth: ALCLS – Nasdaq: CLLS), a biopharmaceutical company focused on developing immunotherapies based on gene-edited CAR T-cells (UCART), announced today that the U.S. Food and Drug Administration (FDA) has approved the Company’s Investigational New Drug (IND) application to initiate a Phase 1 clinical trial for UCARTCS1, in patients with multiple myeloma (MM). The IND for UCARTCS1 was filed on December 28, 2018 and approved by the FDA within a month, on January 25, 2019. Cellectis is the sponsor of the UCARTCS1 clinical study (MUNDI-01) and successfully ensured the manufacturing and release of UCARTCS1 GMP batches, as well as an IRB approval.
- Business Wire
Cellectis Reports 4th Quarter and Full Year 2018 Financial Results
NEW YORK-- -- UCART123 in Phase 1 dose escalation clinical trial ongoing for AML; UCART22 received FDA and IRB approvals for Phase 1 dose escalation clinical trial in B-ALL patients; UCART19 ASH abstract by partners Servier and Allogene showed continued progress of first clinical allogeneic CAR T-cell program for ALL adult and pediatric patients; Cellectis, through its new subsidiary Cellectis Biologics, ...
- Business Wire
Cellectis Enters Lease Agreement to Build Manufacturing Facility, Advancing Towards Commercialization of its UCART Portfolio
Nasdaq: CLLS), a biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), announced that it has entered into a lease agreement to build an 82,000 square foot commercial-scale manufacturing facility named IMPACT (Innovative Manufacturing Plant for Allogeneic Cellular Therapies) in Raleigh, North Carolina, for clinical and commercial production of Cellectis’ leading allogeneic UCART products. In addition, Cellectis started building a 14,000 square foot manufacturing facility in Paris, France named SMART (Starting Material Realization for CAR-T products) to produce Cellectis’ critical starting material supply for UCART clinical studies and commercial products.
- Motley Fool
5 Top Gene-Editing Stocks for 2019
The future of treating disease might be gene editing, and these five stocks have the most promising technologies.
- Business Wire
Cellectis Publishes Novel Methods to Improve the Safety of CAR T-Cell Therapy and Prevent CRS in the Journal of Biological Chemistry
Granulocyte-macrophage colony-stimulating factor inactivation in CAR T-Cells prevents monocyte-dependent release of key cytokine release syndrome mediators
- GlobeNewswire
Consolidated Research: 2019 Summary Expectations for Oceaneering International, Southwest Gas, WellCare Health Plans, Barnes & Noble, Cellectis S.A, and Payment Data — Fundamental Analysis, Key Performance Indications
NEW YORK, Feb. 07, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- Business Wire
Cellectis Appoints William Monteith as Senior Vice President U.S. Manufacturing
Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a biopharmaceutical company focused on developing immunotherapies based on gene-edited CAR T-cells (UCART), today announced the appointment of William (Bill) Monteith to the role of Senior Vice President U.S. Manufacturing. This appointment follows Cellectis’ plan to establish commercial manufacturing capabilities in the U.S., which will be Bill Monteith’s responsibility, notably through the deployment of a proprietary state-of-the-art gene-edited cell manufacturing plant for clinical and commercial supplies of our current immuno-oncology UCART product candidates. Bill Monteith joins Cellectis from Hitachi Chemical Advanced Therapeutics Solutions, where he was the Chief Operating Officer and Site General Manager for three manufacturing facilities.
- Business Wire
Cellectis Reports Financial Results for 3rd Quarter and First Nine Months 2018
NEW YORK-- -- UCART123 in Phase 1 clinical trial for AML and BPDCN patients; UCART22 Phase 1 study protocol approved by FDA for B-ALL patients; UCART19 ASH abstract by partner Servier shows continued progress of first clinical allogeneic CAR T-cell program for ALL patients; UCARTCS1 clinical trial expected to start in 2019 for Multiple Myeloma patients; Cash 1 position of $476M as of September 30, ...
- Business Wire
CAR-T Pioneer Dr. Stephan A. Grupp to Join Cellectis Clinical Advisory Board
Nasdaq: CLLS), a biopharmaceutical company focused on developing immunotherapies based on gene-edited CAR T-cells (UCART), today announced that Stephan A. Grupp, MD, Ph.D., a leading pediatric oncologist at Children's Hospital of Philadelphia and Chief of the Section of Cellular Therapy and Transplant at the Children's Hospital of Philadelphia (CHOP) joined the Company’s Clinical Advisory Board (CAB). Dr. Grupp is a world-renowned pediatric oncologist and cancer researcher who initiated the first pediatric CAR T-cell trial for acute lymphoblastic leukemia at CHOP in 2012.
- Business Wire
Calyxt Appoints CEO, Jim Blome, Former President & CEO of Bayer CropScience LP
Calyxt, Inc. (CLXT) and Cellectis S.A. (NASDAQ: CLLS – EURONEXT GROWTH: ALCLS) announced today the appointment of James A. Blome, former President and CEO of Bayer CropScience LP (North America), as Chief Executive Officer of Calyxt, effective October 1, 2018. Jim Blome will work closely with Calyxt’s Board of Directors to foster the development of the Company’s consumer-focused products, including the upcoming commercial launch of Calyxt’s first product, high-oleic soybean oil. Jim Blome is a high-impact, global leader with over 25 years of leadership experience in the agriculture industry, building teams and strategies with consumer-focused cultures to better meet consumer needs and maximize market share growth.
